-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
State of Emerging Biopharma
Jun 16, 2017
BIO International is one of the most highly anticipated conferences on my agenda. Each year thousands of emerging biotech and pharma leaders come together to talk about innovations, share their accomplishments, and brainstorm the strategies that drive our industry forward.
There are several trends currently shaping the emerging biopharma landscape that will be highlighted at this year’s event. In particular, I’m looking forward to sessions and networking around the use of real-world data and evidence (RWD and RWE) and analytics to support emerging companies’ drug programs and research. Over the past couple of years, we have seen increasing interest in the use of RWE earlier in clinical development, and importantly, the interpretation and applications of these data with data platform and analytics technologies, and industry expertise, to make better decisions about protocol designs and patient recruiting.
BIO has dedicated an entire track to this industry trend, entitled Harnessing Big Data to Drive Innovation in Biomedicine. It will feature several interesting sessions, including a presentation on big data in precision medicine lead by Dr. Atul Butte and John Quackenbush addressing the bottlenecks in translating data to analysis and meaningful interpretation; and another on the challenges and opportunities of big data for emerging biopharma, where David Goldstein, and Guna Rajagopal will discuss how big data is fueling innovation in drug discovery and development.
In alignment with the session track, QuintilesIMS will be unveiling its own solution for emerging biopharma and the underpinning foundation of real world data and evidence that delivers critical insights and helps create value for these customers. As a result of the merger earlier this year between Quintiles and IMS Health, we are able to leverage vast stores of healthcare data and services on behalf of our clients, to help them make insight-driven decisions supporting their overall strategy to advance their assets and drive value for their organization. The application of big data to the development lifecycle is shaping the future of medicine, and we are excited to be a part of this next generation of clinical development and commercialization, aiding the treatment and management of all areas of human disease.
Exploring rare disease research
Another area of interest at BIO are the many sessions focused on rare disease research, which represents huge opportunity across the emerging biopharma landscape. There are currently 449 unique drugs approved for one or more orphan indications, and drugs for rare diseases represented more than 40 percent of new drug approvals in 2014-to-2016.
Two of the rare disease sessions at BIO will include QuintilesIMS experts: Closing the Innovation Gap in Rare Diseases: Where are We Headed? lead by Murray Aitkin, executive director of QuintilesIMS Institute; and Defining and Reflecting Value in Rare Disease Therapies and Payment Approaches, where panelists, including QuintilesIMS VP Adam Sohn and Paul Melmeyer, Associate Director Public Policy at the National Organization of Rare Disorders, will explore the value of biopharmaceuticals and how decisions around patient access and coverage can be guided by value to patients.
BIO brings together a wide range of life sciences and application areas and offers an educational program covering biotech and pharma’s most relevant and timely topics, as well as, amongst other sessions, an executive training program in business development. Outside of the educational sessions, the event provides emerging biopharma experts networking opportunities with industry leaders and investors eager to learn about and discuss the latest innovations in this space. In one of this year’s keynote addresses, former UK Prime Minister, David Cameron, will share insights and reflection on the rapidly changing global landscape as attendees prepare to navigate a potentially transformative political scene.